Convalescent Plasma-mediated Resolution of COVID-19 in a Patient with Humoral Immunodeficiency

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2021 Feb 1

PMID 33521696

Citations 22

Authors

Kazuhito Honjo

Ronnie M Russell

Ran Li

Weimin Liu

Regina Stoltz

Edlue M Tabengwa

Yutao Hua

Lynn Prichard

Ashton N Kornbrust

Sarah Sterrett

Marisa B Marques

Jose L Lima

Chris M Lough

Todd P McCarty

Thomas J Ketas

Theodora Hatziioannou

Paul D Bieniasz

David T Redden

John P Moore

Paul A Goepfert

Sonya L Heath

Beatrice H Hahn

Randall S Davis

Affiliations

Soon will be listed here.

Abstract

Convalescent plasma (CP) is widely used to treat COVID-19, but without formal evidence of efficacy. Here, we report the beneficial effects of CP in a severely ill COVID-19 patient with prolonged pneumonia and advanced chronic lymphocytic leukemia (CLL), who was unable to generate an antiviral antibody response of her own. On day 33 after becoming symptomatic, the patient received CP containing high-titer (ID > 5,000) neutralizing antibodies (NAbs), defervesced, and improved clinically within 48 h and was discharged on day 37. Hence, when present in sufficient quantities, NAbs to SARS-CoV-2 have clinical benefit even if administered relatively late in the disease course. However, analysis of additional CP units revealed widely varying NAb titers, with many recipients exhibiting endogenous NAb responses far exceeding those of the administered units. To obtain the full therapeutic benefits of CP immunotherapy, it will thus be important to determine the neutralizing activity in both CP units and transfusion candidates.

Citing Articles

Synergistic use of Unplanned Reoperation and Hospital Readmission rates for quality monitoring in pediatric surgical care.

Margarita G, Catalina C, Ana B, Belgica C, Sandra M Pediatr Surg Int. 2024; 40(1):312.

PMID: 39550518 DOI: 10.1007/s00383-024-05894-8.

Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.

Qin K, Honjo K, Sherrill-Mix S, Liu W, Stoltz R, Oman A PLoS Med. 2023; 20(6):e1004157.

PMID: 37384638 PMC: 10309642. DOI: 10.1371/journal.pmed.1004157.

Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors.

Sharma S, Rana R, Prakash P, Ganguly N Mol Cell Biochem. 2023; 479(1):127-170.

PMID: 37016182 PMC: 10072821. DOI: 10.1007/s11010-023-04715-1.

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.

Kandula U, Tuji T, Gudeta D, Bulbula K, Mohammad A, Wari K J Blood Med. 2023; 14:159-187.

PMID: 36855559 PMC: 9968437. DOI: 10.2147/JBM.S397722.

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.

Senefeld J, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman E JAMA Netw Open. 2023; 6(1):e2250647.

PMID: 36633846 PMC: 9857047. DOI: 10.1001/jamanetworkopen.2022.50647.

References

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

Harvala H, Mehew J, Robb M, Ijaz S, Dicks S, Patel M . Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro Surveill. 2020; 25(28). PMC: 7376844. DOI: 10.2807/1560-7917.ES.2020.25.28.2001260. View

Wang K, Long Q, Deng H, Hu J, Gao Q, Zhang G . Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clin Infect Dis. 2020; 73(3):e531-e539. PMC: 7454328. DOI: 10.1093/cid/ciaa1143. View

Goodhue Meyer E, Simmons G, Grebe E, Gannett M, Franz S, Darst O . Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay. Transfusion. 2021; 61(4):1160-1170. PMC: 8013397. DOI: 10.1111/trf.16321. View

Cross R, Prasad A, Borisevich V, Woolsey C, Agans K, Deer D . Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. Cell Rep. 2021; 34(10):108837. PMC: 7901292. DOI: 10.1016/j.celrep.2021.108837. View

Casadevall A, Pirofski L . The convalescent sera option for containing COVID-19. J Clin Invest. 2020; 130(4):1545-1548. PMC: 7108922. DOI: 10.1172/JCI138003. View

Arabi Y, Hajeer A, Luke T, Raviprakash K, Balkhy H, Johani S . Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis. 2016; 22(9):1554-61. PMC: 4994343. DOI: 10.3201/eid2209.151164. View

Zheng J, Wong L, Li K, Verma A, Ortiz M, Wohlford-Lenane C . COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2020; 589(7843):603-607. PMC: 7855185. DOI: 10.1038/s41586-020-2943-z. View

Casadevall A, Scharff M . Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995; 21(1):150-61. PMC: 7197598. DOI: 10.1093/clinids/21.1.150. View

10.

Brouwer P, Caniels T, van der Straten K, Snitselaar J, Aldon Y, Bangaru S . Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020; 369(6504):643-650. PMC: 7299281. DOI: 10.1126/science.abc5902. View

11.

Na I, Buckland M, Agostini C, Edgar J, Friman V, Michallet M . Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019; 102(6):447-456. PMC: 6849602. DOI: 10.1111/ejh.13223. View

12.

Joyner M, Bruno K, Klassen S, Kunze K, Johnson P, Lesser E . Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020; 95(9):1888-1897. PMC: 7368917. DOI: 10.1016/j.mayocp.2020.06.028. View

13.

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

14.

Kunisaki K, Janoff E . Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009; 9(8):493-504. PMC: 2775097. DOI: 10.1016/S1473-3099(09)70175-6. View

15.

Klasse P, Moore J . Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. Elife. 2020; 9. PMC: 7311167. DOI: 10.7554/eLife.57877. View

16.

Schmidt F, Weisblum Y, Muecksch F, Hoffmann H, Michailidis E, Lorenzi J . Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020; 217(11). PMC: 7372514. DOI: 10.1084/jem.20201181. View

17.

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View

18.

Chen P, Nirula A, Heller B, Gottlieb R, Boscia J, Morris J . SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020; 384(3):229-237. PMC: 7646625. DOI: 10.1056/NEJMoa2029849. View

19.

Mato A, Roeker L, Lamanna N, Allan J, Leslie L, Pagel J . Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020; 136(10):1134-1143. PMC: 7472711. DOI: 10.1182/blood.2020006965. View

20.

Bryan A, Pepper G, Wener M, Fink S, Morishima C, Chaudhary A . Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol. 2020; 58(8). PMC: 7383515. DOI: 10.1128/JCM.00941-20. View